SWOG 0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).
July 21, 2010
Cancer - Lung
Principal Investigator: Robert A Chapman, MD
The purpose of this research study is to compare the effects, good and/or bad of cetuximab on lung cancer.
Patients must have histologically or cytologically proven newly diagnosed Stage IV, advanced primary non-small cell lung cancer (adenocarcinoma, large cell carcinoma, squamous or unspecified) or recurrent disease after previous surgery and/or irradiation; Patients with controlled (for a minimum of 2 months) brain metastases after treatment, and no residual neurological dysfunction off corticosteroids are eligible; Patients must not have received for any purpose prior chemotherapy, cetuximab, gefitinib, erlotinib or other investigational agents that target the EGFR pathway; Prior radiation is permitted -however patients must have recovered from all associated toxicities at time of registration.